CTIS2023-505122-34-00进行中（未招募）1 期
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis involving Special Areas - 77242113PSO3003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •1. =12 years of age at the screening visit., 2. Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention., 3. Candidate for phototherapy or systemic treatment for plaque psoriasis., 4. Need to meet criteria (a) and/or (b) a. Total BSA =1% at screening and baseline, AND IGA (overall) =2 at screening and baseline AND at least one of the following: - ss-IGA score =3 at screening and baseline, and/or - sPGA-G =3 at screening and baseline, and/or - hf-PGA score =3 at screening and baseline., 5. Failed to respond to at least 1 topical therapy used for treatment of psoriasis.
排除标准
- •1. Nonplaque form of psoriasis., 2. Dermatoses other than plaque psoriasis or palmoplantar pustulosis of the palmoplantar area., 3. Current drug-induced psoriasis., 4. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances., 5. Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients.
研究者
相似试验
招募中
1 期
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and RetreatmentModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code: 10071117Term: Plaque psoriasis Class: 10040785CTIS2023-505120-59-00Janssen - Cilag International600
进行中（未招募）
不适用
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial ofUstekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody,Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis andPreviously Treated with Biologic Anti-TNFa Agent(s)EUCTR2009-012265-60-FRCentocor B.V.300
进行中（未招募）
不适用
A Study of the Safety and Efficacy of Ustekinumab in Patients with Psoriatic ArthritisPsoriatic ArthritisEUCTR2009-012264-14-LTJanssen-Cilag International N.V.600
进行中（未招募）
1 期
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of AdolescentSubjects With Moderate to Severe Plaque-type Psoriasis - CADMUSModerate to Severe Plaque-type PsoriasisMedDRA version: 12.0Level: LLTClassification code 10037153Term: PsoriasisEUCTR2009-014368-20-FRCentocor BV110
进行中（未招募）
1 期
A Study of the Safety and Efficacy of Ustekinumab in Patients with Psoriatic Arthritis.Psoriatic ArthritisEUCTR2009-012264-14-GBJanssen-Cilag Internation N.V.